MAPK8 and diffuse large B-cell lymphoma: Specifically, high-risk subgroup exhibited marked sensitivity to NSC.87,877 (paclitaxel), FH535, Ebelin, bleomycin, FTI.277 (Farnesyltransferase Inhibitor), JNK.9 L (JNK inhibitor), nilotinib, and Z.LLNle.CHO (p < 0.001), suggesting their potential as targeted therapeutics for chemoresistant DLBCL.